Add-on montelukast in inadequately controlled asthma patients in a 6-month op…

Bronchial asthma often remains uncontrolled despite treatment with inhaled corticosteroids (ICS), long-acting b2-agonists (LABA) or both, necessitating additional treatment. Patients 18 years (n Z 1681) with mild-to-moderate asthma received oral montelukast 10 mg added to ICS or ICS þ LABAs, and were followed for 6 months in a prospective, open-label observational study. The primary endpoint …

Role of Montelukast in Asthma and Allergic rhinitis patients

Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects

Clinical, Physiological and AntiInflammatory Effect of Montelukast in Patient…

Cough variant asthma (CVA) is a phenotype of asthma presenting solely with coughing, characterized by airway hyperresponsiveness, eosinophilic inflammation and a cough response to bronchodilators. Leukotriene receptor antagonists (LTRAs) are antiasthma medications with antiinflammatory and bronchodilatory properties. Although LTRAs exert antitussive effects in CVA, the mechanisms involved are u…

Effects of treatment with montelukast alone, budesonide/formoterol alone and …

Whether cysteinyl-leukotriene receptor antagonists (LTRAs) have a similar antitussive effect to inhaled corticosteroids and long-acting β2-agonist (ICS/LABA), and that LTRA plus ICS/LABA is superior to LTRAs alone or ICS/LABA alone in treating cough variant asthma (CVA) remain unclear. This study aimed to investigate and compare the efficacy of montelukast alone, budesonide/formoterol alone an…

Common Eye Diseases and their Management

It is a pleasure to welcome two new authors who have contributed to the third edition of “Common Eye Diseases”: Peter Galloway and Andrew Browning. Six years have passed since the last edition but even in this relatively short time there have been significant advances in the diagnosis and management of eye disease and an update has become necessary. Each author has taken a block of chapter…

Effectiveness of Ciprofloxacin, Levofloxacin, or Moxifloxacin for Treatment o…

The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillin sensitive or methicillin-resistant S. aureus (MSSA or MRSA,…

Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into…

We aimed to quantify the penetration of ciprofloxacin, ofloxacin, and moxifloxacin into the cornea and aqueous humor of cadaver eyes. A total of 60 enucleated eyes, not eligible for corneal transplantation, were divided into three groups and immersed in commercial solutions of 0.3% ciprofloxacin, 0.3% ofloxacin, or 0.5% moxifloxacin for 10 min. Whole corneas and samples of aqueous humor were th…

Moxifloxacin: a review of the microbiological, pharmacological, clinical and …

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Moxifloxacin

Moxifloxacin (MOXI: 8-methoxy-quinolone), and quinolones in general, exert their effects by trapping a DNA drug enzyme complex and specifically inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV.

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and S…

Intravenous/oral moxifloxacin therapy was efficacious and safe for hospitalized elderly patients with CAP, achieving 190% cure in all severity and age subgroups, and was associated with faster clinical recovery than intravenous/oral levofloxacin therapy, with a comparable safety profile.